6GJG

Plasmodium falciparum dihydroorotate dehydrogenase DHODH in complex with 3,6-dimethyl-N-(4-(trifluoromethyl)phenyl)-(1,2)oxazolo(5,4-d)pyrimidin-4-amine

6GJG の概要

• エントリーDOI: 10.2210/pdb6gjg/pdb
• 分子名称: Dihydroorotate dehydrogenase (quinone), mitochondrial, FLAVIN MONONUCLEOTIDE, OROTIC ACID, ... (5 entities in total)
• 機能のキーワード: enzyme, dhodh, flavoprotein
• 由来する生物種: Plasmodium falciparum (isolate 3D7)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 92613.23

構造登録者

Rowland, P. (登録日: 2018-05-16, 公開日: 2018-09-19, 最終更新日: 2024-05-15)

主引用文献

Kokkonda, S.,El Mazouni, F.,White, K.L.,White, J.,Shackleford, D.M.,Lafuente-Monasterio, M.J.,Rowland, P.,Manjalanagara, K.,Joseph, J.T.,Garcia-Perez, A.,Fernandez, J.,Gamo, F.J.,Waterson, D.,Burrows, J.N.,Palmer, M.J.,Charman, S.A.,Rathod, P.K.,Phillips, M.A.
Isoxazolopyrimidine-Based Inhibitors ofPlasmodium falciparumDihydroorotate Dehydrogenase with Antimalarial Activity.
ACS Omega, 3:9227-9240, 2018

PubMed Abstract: Malaria kills nearly 0.5 million people yearly and impacts the lives of those living in over 90 countries where it is endemic. The current treatment programs are threatened by increasing drug resistance. Dihydroorotate dehydrogenase (DHODH) is now clinically validated as a target for antimalarial drug discovery as a triazolopyrimidine class inhibitor () is currently undergoing clinical development. We discovered a related isoxazolopyrimidine series in a phenotypic screen, later determining that it targeted DHODH. To determine if the isoxazolopyrimidines could yield a drug candidate, we initiated hit-to-lead medicinal chemistry. Several potent analogues were identified, including a compound that showed in vivo antimalarial activity. The isoxazolopyrimidines were more rapidly metabolized than their triazolopyrimidine counterparts, and the pharmacokinetic data were not consistent with the goal of a single-dose treatment for malaria.

PubMed: 30197997
DOI: 10.1021/acsomega.8b01573

実験手法

X-RAY DIFFRACTION (1.99 Å)